What's wrong with our cancer models?

Oncology, as a therapeutic area, is characterized by a desperate medical need for new drugs; the use of drugs that kill cells and which are consequently often toxic; and rates of failure in expensive Phase III trials that eclipse many other disease areas. The poor performance of most investigational cancer drugs implies that the standard preclinical disease models are faulty or, at least, improperly used. Some studies, however, support the view that cancer models can be highly effective, but only when selected and interpreted with care.

[1]  A. Berns,et al.  Conditional mouse models of sporadic cancer , 2002, Nature Reviews Cancer.

[2]  B. Druker.  Imatinib as a paradigm of targeted therapies , 2003 .

[3]  A. Kamb.  Consequences of nonadaptive alterations in cancer. , 2003, Molecular biology of the cell.

[4]  L. Seymour,et al.  Clinical predictive value of the in vitro cell line, human xenograft, and mouse allograft preclinical cancer models. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.

[5]  M. Christian,et al.  Relationships between drug activity in NCI preclinical in vitro and in vivo models and early clinical trials , 2001, British Journal of Cancer.

[6]  J. Griffin,et al.  Resistance to imatinib (Glivec): update on clinical mechanisms. , 2003, Drug resistance updates : reviews and commentaries in antimicrobial and anticancer chemotherapy.

[7]  D. Botstein,et al.  A gene expression database for the molecular pharmacology of cancer , 2000, Nature Genetics.

[8]  Jonathan M. Yingling,et al.  Development of TGF-β signalling inhibitors for cancer therapy , 2004, Nature Reviews Drug Discovery.

[9]  C. Sawyers,et al.  Molecular mechanisms of resistance to STI571 in chronic myeloid leukemia , 2002, Current opinion in hematology.

[10]  D. Slamon,et al.  Rationale for trastuzumab (Herceptin) in adjuvant breast cancer trials. , 2001, Seminars in oncology.

[11]  I. Kola,et al.  Can the pharmaceutical industry reduce attrition rates? , 2004, Nature Reviews Drug Discovery.

[12]  J. Dancey.  Predictive factors for epidermal growth factor receptor inhibitors--the bull's-eye hits the arrow. , 2004, Cancer cell.

[13]  T. Jacks,et al.  STI571 inactivation of the gastrointestinal stromal tumor c-KIT oncoprotein: biological and clinical implications , 2001, Oncogene.

[14]  S. L. Wong,et al.  Combining biological networks to predict genetic interactions. , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[15]  P. Houghton,et al.  Integrating pharmacology and in vivo cancer models in preclinical and clinical drug development. , 2004, European journal of cancer.

[16]  J. Griffin.  FLT3 tyrosine kinase as a target in acute leukemias. , 2004, The hematology journal : the official journal of the European Haematology Association.

[17]  Elkan F Halpern,et al.  Trends in the risks and benefits to patients with cancer participating in phase 1 clinical trials. , 2004, JAMA.

[18]  Masaru Tomita,et al.  Toward large-scale modeling of the microbial cell for computer simulation. , 2004, Journal of biotechnology.